| major catalyst | x |
| premarket gap-up | x |
| hold premarket high as support | x |
| holds gains after lunch | x |
| 3-5x volume | x |
| breaks resistance on daily | x |
catalyst :
Bellus Health shares are trading higher after the company announced its Phase 2b SOOTHE trial of BLU-5937 achieved its primary endpoint.
No comments:
Post a Comment